Peptide stacking for cognitive enhancement has exploded in biohacker and nootropic communities. The combination of Semax, Selank, and Dihexa, sometimes called "the cognition stack," targets three distinct neuroscience pathways: neurotrophic factor production, inhibitory neurotransmitter modulation, and growth-factor-driven synaptogenesis.

The rationale is pharmacologically elegant. But the distance between the rationale and the evidence is something most guides gloss over. Here, we'll go deep on what each compound actually does at the molecular level, what the research actually shows (and where it stops), why combining them makes theoretical sense, and what the real risks are.

The Three-Pathway Model: Why These Three Peptides

The logic behind combining Semax, Selank, and Dihexa rests on the premise that optimal cognition requires support across multiple neurological domains simultaneously. Each peptide addresses a fundamentally different bottleneck:

Think of it as a construction analogy: Semax provides the building materials (neurotrophic factors that keep neurons healthy and growth-capable), Selank clears the noise from the worksite (reducing anxiety and excessive neural excitation so the brain can function in an optimal state), and Dihexa builds the new connections (directly stimulating synapse formation between neurons). None of these mechanisms duplicate the others; they stack vertically across different levels of the cognitive system.

Semax: The Neurotrophic Engine

What Semax Actually Is

Semax is a synthetic analog of the ACTH(4-10) fragment, the portion of adrenocorticotropic hormone that researchers discovered in the 1950s had cognitive effects independent of ACTH's hormonal activity. Native ACTH fragments degraded in minutes, making them therapeutically useless. In the 1970s-80s, scientists at the Russian Academy of Sciences solved this by attaching a Pro-Gly-Pro (PGP) tripeptide to the C-terminus, creating a molecule that resisted enzymatic degradation and extended its active duration dramatically (Kolomin et al., 2013).

The critical design achievement: Semax retains ACTH's neurotrophic effects without activating glucocorticoid receptors. This means it influences brain function without cortisol elevation, HPA axis disruption, or the hormonal side effects that make native ACTH problematic for cognitive applications.

Mechanism of Action: Three Parallel Pathways

1. BDNF / Neurotrophin Axis (Primary Mechanism)

The most validated mechanism is Semax's modulation of brain-derived neurotrophic factor (BDNF) and related neurotrophins. BDNF is the primary growth factor supporting neuron survival, synaptic plasticity, and the structural changes underlying learning and memory.

Dolotov et al. (2006) demonstrated that a single intranasal application of Semax (50 μg/kg) in rats produced a 1.4-fold increase in BDNF protein levels in the hippocampus, accompanied by a 1.6-fold increase in TrkB receptor phosphorylation and a 3-fold increase in BDNF mRNA expression. Semax-treated animals showed significantly improved conditioned avoidance task performance, a direct cognitive outcome linked to the BDNF increase.

A follow-up study (Dolotov et al., 2009) mapped the temporal dynamics: Semax activates BDNF and NGF expression in a region-specific pattern across hippocampus, frontal cortex, and retina, with the hippocampus showing the strongest and most sustained response, peaking at 3-8 hours post-administration.

2. Immunomodulatory / Anti-inflammatory Pathway

A genome-wide transcriptome analysis by Medvedeva et al. (2014) revealed something unexpected: under ischemic conditions, Semax modulated over 1,500 genes, and the immune system was the most significantly affected category, not direct neuronal genes. Semax enhanced leukocyte activation, dendritic cell function, and immunoglobulin expression in damaged brain tissue.

This is relevant because neuroinflammation is increasingly recognized as a driver of cognitive decline and brain fog. RNA-Seq analysis (Dergunova et al., 2020) showed Semax suppresses inflammatory gene expression and activates anti-inflammatory pathways, suggesting it may improve cognition partly by reducing the low-grade neuroinflammation caused by chronic stress, sleep deprivation, or aging.

3. Melanocortin System Modulation

As an ACTH-derived peptide, Semax interacts with the melanocortin receptor system (MC1R-MC5R), which is involved in attention, arousal, motivation, and stress response. Through this pathway, Semax appears to influence dopaminergic signaling, contributing to its reported effects on focus and mental energy without the jitteriness of stimulants. Research has also suggested Semax may augment the effects of psychostimulants on central dopamine release, which has implications for attention-deficit conditions.

Semax Human Evidence

Selank: The GABAergic Stabilizer

What Selank Actually Is

Selank is a synthetic analog of tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) found in the heavy chain of human immunoglobulin G (IgG). Tuftsin's primary role in the body is immunomodulatory; it regulates phagocyte activity and immune cell function. But researchers at the Russian Academy of Sciences discovered that tuftsin also had neurocognitive effects, and they extended its sequence with the same Pro-Gly-Pro tripeptide used in Semax to improve metabolic stability and half-life.

The result is a peptide that bridges two systems (immune regulation and neurotransmitter modulation) in a way that no conventional anxiolytic drug does. This dual mechanism is central to why Selank behaves so differently from benzodiazepines despite producing similar anxiolytic effects.

Mechanism of Action: Four Interlocking Systems

1. GABAergic Modulation (Core Anxiolytic Mechanism)

A landmark study by Kasian et al. (2016) in Frontiers in Pharmacology mapped Selank's effects on GABA-related gene expression in rat frontal cortex. The findings were striking: of 84 genes involved in GABAergic neurotransmission, 52 showed altered expression after Selank administration, with 7 showing particularly heavy modulation. The changes correlated positively with those produced by GABA itself, confirming that Selank's anxiolytic mechanism operates through the same receptor system as benzodiazepines.

However, Selank appears to modulate GABA-A receptors through an allosteric mechanism that changes receptor affinity for GABA rather than directly activating the receptor (which is what benzodiazepines do). This distinction is crucial; it may explain why Selank produces anxiolysis without the sedation, amnesia, dependence, and withdrawal that plague benzodiazepine therapy.

2. Enkephalin Preservation

Research has demonstrated that Selank inhibits enkephalinase, the enzyme that degrades enkephalins, the body's natural opioid-like anxiolytic peptides. People with anxiety disorders show elevated enkephalinase activity, meaning their natural calming peptides are broken down faster. By protecting enkephalins from degradation, Selank may restore the body's own anxiety-buffering system rather than imposing an external pharmacological effect.

A study comparing mouse strains confirmed this: BALB/c mice (high enkephalinase activity, anxiety-prone) showed significant anxiolytic response to Selank, while C57Bl/6 mice (low enkephalinase, naturally calm) showed no behavioral change, supporting the idea that Selank works by correcting a deficit rather than creating an artificial effect.

3. Serotonergic and Dopaminergic Regulation

Selank modulates monoamine neurotransmitter levels, including serotonin, dopamine, and norepinephrine. This multi-transmitter modulation distinguishes it from drugs that target single systems (SSRIs for serotonin, benzodiazepines for GABA). The serotonergic effects contribute to mood stability, while dopamine modulation may enhance motivation and the cognitive effort required for sustained mental work.

4. Immunomodulatory Effects and BDNF

As a tuftsin analog, Selank retains significant immune-regulatory properties. It modulates IL-6 expression (a key inflammatory cytokine), influences T-helper cell balance, and has shown antiviral activity against the H3N2 influenza strain in both in-vitro and in-vivo models. Intriguingly, Selank has also been found to rapidly elevate BDNF expression in the hippocampus, creating an overlap with Semax that may be additive rather than redundant, since the two peptides reach BDNF through different upstream pathways.

Selank Human Evidence

Dihexa: The Synaptogenic Powerhouse

What Dihexa Actually Is

Dihexa is a synthetic derivative of angiotensin IV (AngIV), a fragment of the renin-angiotensin system that, somewhat unexpectedly, was discovered to have cognitive effects alongside its cardiovascular functions. Dr. Joseph Harding's group at Washington State University spent years studying AngIV analogs for cognitive enhancement, but the native molecule couldn't cross the blood-brain barrier. Dihexa was designed specifically to solve this problem: it's orally bioavailable, BBB-permeable, and metabolically stable, with a remarkably long circulating half-life of approximately 12.7 days after IV administration in rats (McCoy et al., 2013).

Dihexa is pharmacologically unique among nootropic peptides because it doesn't work through neurotransmitter modulation, receptor agonism, or neurotrophin production. Instead, it operates through an entirely different system: the hepatocyte growth factor (HGF)/c-Met receptor pathway.

The HGF/c-Met Mechanism: Building New Synapses

The landmark study by Benoist et al. (2014), published in the Journal of Pharmacology and Experimental Therapeutics, elucidated Dihexa's mechanism. The key findings:

Dihexa binds directly to hepatocyte growth factor (HGF) with high affinity. When Dihexa binds HGF in the presence of even subthreshold concentrations of the growth factor, it creates an active HGF-Dihexa heterodimer that triggers c-Met receptor phosphorylation, activating the downstream signaling cascades (PI3K/Akt, MAPK/ERK) that drive cellular growth, repair, and connectivity.

In brain tissue specifically, this c-Met activation promotes:

In their neurotrophic activity assay, Dihexa was found to be seven orders of magnitude (10 million times) more potent than BDNF. This number is dramatic but requires context: it refers to the concentration needed to promote neurite outgrowth in a specific in-vitro assay, not to "brain-boosting power" in any holistic sense. BDNF and Dihexa work through completely different receptors and signaling cascades. The comparison describes assay potency, not clinical superiority.

Dihexa Animal Evidence

The Synergy Rationale: How the Three Interact

The theoretical synergy between these three peptides isn't just "more is better." There are specific mechanistic reasons why they might amplify each other's effects:

Semax → Selank synergy: BDNF has been shown to modulate GABAergic interneuron function and improve inhibitory circuit efficiency. By elevating BDNF, Semax may enhance the substrate that Selank acts upon, making GABAergic modulation more effective. Both peptides also independently elevate BDNF through different mechanisms (Semax via melanocortin pathways, Selank via immune/enkephalin pathways), potentially producing additive neurotrophic effects.

Selank → Dihexa synergy: Long-term potentiation (the process Dihexa enhances via HGF/c-Met) is impaired by excessive stress hormones and neural noise. By stabilizing GABAergic tone and reducing anxiety-driven cortisol, Selank may create optimal conditions for LTP, making Dihexa's synaptic strengthening more effective and durable.

Semax → Dihexa synergy: New synapses formed under Dihexa's HGF stimulation need neurotrophic support to survive and integrate into functional circuits. Without adequate BDNF and NGF, newly formed synapses may be pruned. Semax's elevation of these growth factors may increase the survival rate of Dihexa-generated connections, the "build it AND maintain it" logic.

Practical Protocol: Dosing, Timing, and Cycling

The following protocols are drawn from community consensus, practitioner recommendations, and extrapolation from individual compound research. They are not clinically validated.

Administration Overview

Recommended Onboarding Sequence

Don't start all three simultaneously. This makes it impossible to identify which compound is producing which effects, and prevents isolating any adverse reactions.

Cycling Protocol

Regular breaks maintain sensitivity and reduce unknown long-term risks. The standard approach:

Important: Dihexa warrants shorter cycles and longer breaks than Semax or Selank given its extreme potency and the theoretical HGF/c-Met safety concern. Some practitioners recommend limiting Dihexa to 4-week blocks maximum with extended off periods, while Semax and Selank can be used on the standard 6/2 cycle.

Safety Profile and Risk Assessment

Each compound has a different risk profile, and combining them creates additional unknowns.

Who This Stack Is (and Isn't) For

Cost and Sourcing Realities

Measuring Whether It's Working

Subjective feelings of "better focus" are unreliable for assessing nootropic effects due to placebo response and expectation bias. Here's a more rigorous approach:

If This Stack Isn't Right: Alternatives

Key Takeaways

The most conservative approach: start with Semax + Selank only (solid evidence, established safety), and consider adding Dihexa only if the two-peptide stack is well-tolerated and insufficient for your needs. Physician oversight, baseline bloodwork, and objective cognitive tracking should be considered non-negotiable, not optional.

What makes this stack interesting isn't that any single component is a breakthrough; it's that the three mechanisms genuinely don't overlap. In a field full of redundant nootropic stacking (five things that all raise acetylcholine), this combination represents a more sophisticated pharmacological approach. Whether that sophistication translates into meaningful real-world cognitive enhancement in healthy humans remains an open question that only rigorous clinical research can answer.

References

Dolotov OV et al. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 1117(1):54-60. PMID: 16996037.
Dolotov OV et al. (2009). Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. J Mol Neurosci. 38(2):127-35. PMID: 19662538.
Medvedeva EV et al. (2014). The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 15:228. PMC3987924.
Dergunova LV et al. (2020). Novel insights into protective properties of ACTH(4-7)PGP (Semax) peptide at the transcriptome level following cerebral ischaemia–reperfusion in rats. Genes. 11(6):681.
Kolomin TA et al. (2013). Transcriptomic response of rat hippocampus and spleen to Semax. Regulatory Peptides. Cited in Cognitive Vitality review, Alzheimer's Drug Discovery Foundation.
Gusev EI et al. (2017). Semax in prevention of disease progress in patients with ischemic stroke. BDNF and rehabilitation data. [Referenced in Cognitive Vitality review].
Kasian A et al. (2016). Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Front Pharmacol. 7:31. PMC4757669.
Volkova A et al. (2017). GABA, Selank, and olanzapine affect the expression of genes involved in GABAergic neurotransmission in IMR-32 cells. Front Pharmacol. 8:89.
Kolik LG et al. (2019). Selank protects against ethanol-induced memory impairment by regulating BDNF content in hippocampus and prefrontal cortex. Bull Exp Biol Med. 167(5):641-644.
Benoist CC et al. (2014). The procognitive and synaptogenic effects of angiotensin IV–derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system. J Pharmacol Exp Ther. 351(2):390-402. PMC4201273.
McCoy AT et al. (2013). Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther. 344(1):141-54.
Sun XJ et al. (2021). AngIV-analog dihexa rescues cognitive impairment and recovered memory in the APP/PS1 mouse via the PI3K/AKT signaling pathway. Brain Sci. 11(11):1487.
Wright JW, Harding JW (2021). Small molecule activation of the neurotrophin hepatocyte growth factor to treat Alzheimer disease. Ageing Neurodegener Dis. 1:2.